Spyre Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Waltham, MA
SYRE chart
What traders are saying about $SYRE
Latest postsSpyre Therapeutics, Inc. news
- Spyre Therapeutics investigates SPY003 as innovative monotherapy and combination approach
Traders Union ·
- How Upcoming UEGW 2026 Data Will Impact Spyre Therapeutics Stock
Simply Wall Street ·
- Spyre Therapeutics (SYRE) After UEGW 2026 Buzz, Is Its Valuation Already Priced In?
Simply Wall Street ·
- Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview
Yahoo Finance ·
- Spyre Therapeutics, Inc. Estimates – NASDAQ:SYRE
TradingView ·
- Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says
Yahoo Finance ·
- Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
Yahoo Finance ·
- Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering
Yahoo Finance ·
- Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
tikr.com ·
- Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
Yahoo Finance ·
- Spyre Therapeutics stock falls on public offering launch
Yahoo Finance ·
- Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Yahoo Finance ·
Spyre Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $886,000 | $2.3M |
| Net income | -$155.2M | -$208.0M | -$338.8M | -$83.8M |
| Diluted EPS | – | – | $13.76 | $-24.86 |
| Total assets (year end) | $777.8M | $608.5M | $341.9M | $71.1M |
| Cash and equivalents (year end) | $85.7M | $89.4M | $188.9M | $34.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Spyre Therapeutics, Inc.
- Ticker
- SYRE (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1636282
- Former names
- Aeglea BioTherapeutics, Inc.
Frequently asked questions
What exchange is Spyre Therapeutics, Inc. listed on?
Spyre Therapeutics, Inc. trades on the Nasdaq under the ticker symbol SYRE.
What industry is Spyre Therapeutics, Inc. in?
Spyre Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Spyre Therapeutics, Inc. headquartered?
Spyre Therapeutics, Inc.'s business address on file with the SEC is in Waltham, MA.
When does Spyre Therapeutics, Inc.'s fiscal year end?
Spyre Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Spyre Therapeutics, Inc. report?
Spyre Therapeutics, Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.